GOSS – Gossamer Bio Inc.
GOSS
$11.20Name : Gossamer Bio, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $68,503,576.00
EPSttm : -52.8
Gossamer Bio, Inc.
$11.20
GOSS — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
25.65
Margin Of Safety %
Put/Call OI Ratio
0.07
EPS Next Q Diff
11.07
EPS Last/This Y
41.99
EPS This/Next Y
2.4
Price
11.25
Target Price
95.4
Analyst Recom
2.25
Performance Q
-20.61
Upside
-17,373.5%
Beta
2.26
Ticker: GOSS
22 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | GOSS | 9.22 | 0.07 | 0.02 | 66674 |
| 2026-10-13 | GOSS | 9.84 | 0.07 | 999.99 | 66668 |
| 2026-10-14 | GOSS | 8.9 | 0.07 | 0.00 | 66667 |
| 2026-10-15 | GOSS | 8.87 | 0.07 | 0.00 | 66631 |
| 2026-10-16 | GOSS | 8.67 | 0.07 | 999.99 | 66630 |
| 2026-10-19 | GOSS | 8.35 | 0.07 | 9.00 | 66630 |
| 2026-10-20 | GOSS | 9.52 | 0.07 | 0.00 | 66415 |
| 2026-10-21 | GOSS | 9.93 | 0.07 | 0.00 | 66420 |
| 2026-10-22 | GOSS | 9.44 | 0.07 | 999.99 | 66421 |
| 2026-10-23 | GOSS | 9.78 | 0.07 | 999.99 | 66421 |
| 2026-10-26 | GOSS | 9.22 | 0.07 | 0.00 | 66334 |
| 2026-10-27 | GOSS | 9.65 | 0.07 | 0.00 | 66334 |
| 2026-10-28 | GOSS | 10.79 | 0.07 | 0.00 | 66334 |
| 2026-10-29 | GOSS | 10.64 | 0.07 | 0.00 | 66334 |
| 2026-10-30 | GOSS | 10.32 | 0.07 | 0.00 | 66332 |
| 2026-11-02 | GOSS | 9.39 | 0.07 | 0.00 | 66331 |
| 2026-11-03 | GOSS | 9.28 | 0.07 | 0.10 | 66325 |
| 2026-11-04 | GOSS | 9.93 | 0.07 | 999.99 | 66318 |
| 2026-11-05 | GOSS | 9.54 | 0.07 | 0.02 | 66316 |
| 2026-11-06 | GOSS | 9.96 | 0.07 | 0.00 | 66305 |
| 2026-11-09 | GOSS | 10.48 | 0.07 | 0.06 | 66310 |
| 2026-11-10 | GOSS | 11.26 | 0.07 | 0.00 | 66308 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
22 items
«
‹
Current Page1 of 1
›
»
22 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | GOSS | 9.31 | 76.6 | - | -18.01 |
| 2026-10-13 | GOSS | 9.76 | 76.6 | - | -18.01 |
| 2026-10-14 | GOSS | 8.94 | 76.6 | - | -18.01 |
| 2026-10-15 | GOSS | 8.88 | 76.6 | - | -18.01 |
| 2026-10-16 | GOSS | 8.76 | 76.6 | - | -18.01 |
| 2026-10-19 | GOSS | 8.42 | 76.6 | - | -18.01 |
| 2026-10-20 | GOSS | 8.42 | 76.6 | - | -18.01 |
| 2026-10-21 | GOSS | 9.59 | 76.6 | - | -18.01 |
| 2026-10-22 | GOSS | 9.44 | 76.6 | - | -18.01 |
| 2026-10-23 | GOSS | 9.67 | 76.6 | - | -18.01 |
| 2026-10-26 | GOSS | 9.22 | 76.6 | - | -18.01 |
| 2026-10-27 | GOSS | 9.71 | 76.6 | - | -18.01 |
| 2026-10-28 | GOSS | 10.73 | 76.6 | - | -18.01 |
| 2026-10-29 | GOSS | 10.67 | 76.6 | - | -18.01 |
| 2026-10-30 | GOSS | 10.38 | 76.6 | - | -18.01 |
| 2026-11-02 | GOSS | 9.38 | 76.6 | - | -18.01 |
| 2026-11-03 | GOSS | 9.31 | 76.6 | - | -18.01 |
| 2026-11-04 | GOSS | 9.95 | 76.6 | - | -18.01 |
| 2026-11-05 | GOSS | 9.44 | 76.6 | - | -18.01 |
| 2026-11-06 | GOSS | 9.75 | 76.6 | - | -18.01 |
| 2026-11-09 | GOSS | 10.60 | 76.6 | - | -18.01 |
| 2026-11-10 | GOSS | 11.25 | 76.6 | - | -18.01 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
22 items
«
‹
Current Page1 of 1
›
»
21 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | GOSS | 0.00 | 0 | 22.10 |
| 2026-10-13 | GOSS | 0.00 | 0 | 22.10 |
| 2026-10-14 | GOSS | 0.00 | 0 | 22.10 |
| 2026-10-15 | GOSS | 0.00 | 0 | 22.10 |
| 2026-10-16 | GOSS | 0.00 | 0 | 22.10 |
| 2026-10-19 | GOSS | 0.00 | 10.16 | 22.10 |
| 2026-10-20 | GOSS | 0.00 | 10.16 | 22.10 |
| 2026-10-21 | GOSS | 0.00 | 10.16 | 22.10 |
| 2026-10-22 | GOSS | 0.00 | 10.16 | 22.10 |
| 2026-10-23 | GOSS | 0.00 | 10.16 | 22.10 |
| 2026-10-26 | GOSS | 0.00 | 36.70 | 22.10 |
| 2026-10-27 | GOSS | 0.00 | 36.70 | 25.65 |
| 2026-10-28 | GOSS | 0.00 | 36.70 | 25.65 |
| 2026-10-29 | GOSS | 0.00 | 36.70 | 25.65 |
| 2026-10-30 | GOSS | 0.00 | 36.70 | 25.65 |
| 2026-11-02 | GOSS | 0.00 | 36.72 | 25.65 |
| 2026-11-03 | GOSS | 0.00 | 36.72 | 25.65 |
| 2026-11-05 | GOSS | 0.00 | 36.72 | 25.65 |
| 2026-11-06 | GOSS | 0.00 | 36.72 | 25.65 |
| 2026-11-09 | GOSS | 0.00 | 56.39 | 25.65 |
| 2026-11-10 | GOSS | 0.00 | 56.39 | 25.65 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
21 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
-16
Avg. EPS Est. Current Quarter
-3.93
Avg. EPS Est. Next Quarter
-4.93
Insider Transactions
Institutional Transactions
56.39
Beta
2.26
Average Sales Estimate Current Quarter
10
Average Sales Estimate Next Quarter
3
Fair Value
Quality Score
12
Growth Score
22
Sentiment Score
44
Actual DrawDown %
99.1
Max Drawdown 5-Year %
-99.3
Target Price
95.4
P/E
Forward P/E
PEG
P/S
1.29
P/B
P/Free Cash Flow
EPS
-55.67
Average EPS Est. Cur. Y
-18.01
EPS Next Y. (Est.)
-15.61
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-235
Relative Volume
0.37
Return on Equity vs Sector %
106.9
Return on Equity vs Industry %
126.6
EPS 1 7Days Diff
-1.7
EPS 1 30Days Diff
-3.61
EBIT Estimation
◆
GOSS
Healthcare
$11.28
📉
N/A
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
6/20
Pullback
4/25
Volume
11/15
Valuation
12/20
TP/AR
5/10
Options
8/10
RSI
58.7
Range 1M
82.5%
Sup Dist
14.9%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
4/25
Growth
20/30
Estimates
6/20
Inst/Vol
5/15
Options
6/10
EPS Yr
74%
EPS NY
32.7%
52W%
0.9%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+745.7% upside
Quality
8/30
Valuation
16/30
Growth
17/25
Stability
6/10
LT Trend
1/5
Upside
+745.7%
Quality
12
Click a card to see score breakdown
Full Analysis →
GOSS — P/E HistoricalBiotechnology
Sector: Healthcare
Industry: Biotechnology
Employees: 161
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
GOSS
Latest News
—
Caricamento notizie per GOSS…
stock quote shares GOSS – Gossamer Bio Inc. Stock Price stock today
news today GOSS – Gossamer Bio Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch GOSS – Gossamer Bio Inc. yahoo finance google finance
stock history GOSS – Gossamer Bio Inc. invest stock market
stock prices GOSS premarket after hours
ticker GOSS fair value insiders trading